文献速递临床试验与 GCP基础与转化研究

基于高敏肌钙蛋白状态使用β受体阻滞剂治疗创伤性脑损伤(BBTBBT):双盲随机对照临床试验的方法学与方案实施

Beta blocker use in traumatic brain injury based on the high-sensitive troponin status (BBTBBT): methodology and protocol implementation of a double-blind randomized controlled clinical trial.
PubMed 文献 · Trials · 2021-12-07

BBTBBT研究是一项前瞻性、随机、双盲、安慰剂对照三臂试验,旨在确定基于高敏肌钙蛋白T(HsTnT)状态早期使用普萘洛尔能否改善创伤性脑损伤(TBI)患者结局。研究假设早期使用普萘洛尔可降低TBI患者10天和30天死亡率,次要结局包括血清生物标志物与损伤严重程度的相关性及β受体阻滞剂对住院时长和3个月功能状态的影响。

要点

  • 基于HsTnT状态分层:阳性者接受β受体阻滞剂(组1),阴性者随机接受普萘洛尔(组2)或安慰剂(组3)。
  • 研究治疗时间窗为伤后首个24小时,所有入组患者在伤后首个4和6小时检测HsTnT。
  • 主要结局为10天和30天死亡率,次要结局包括生物标志物相关性、住院时长和3个月功能状态。

核心结论

  • 早期使用β受体阻滞剂可能减轻儿茶酚胺风暴及随后与TBI相关的免疫和炎症变化级联反应。
  • HsTnT可能成为TBI患者有用的快速诊断和预后工具。
  • 该研究将为改善TBI患者生存和功能结局提供重要临床信息。

研究设计与样本

  • BBTBBT研究是一项前瞻性、随机、双盲、安慰剂对照三臂试验,纳入轻至重度TBI患者,基于HsTnT状态分组。
  • 所有入组患者在伤后首个4和6小时检测HsTnT。
  • HsTnT阳性且无禁忌症者接受β受体阻滞剂(组1);HsTnT阴性者随机接受普萘洛尔(组2)或安慰剂(组3)。
  • 研究治疗时间窗为伤后首个24小时。
  • 试验注册号ClinicalTrials.gov NCT04508244,于2020年8月7日注册;招募于2020年12月29日开始并正在进行。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Beta-adrenergic receptor blockers (BB) play an important role in the protection of organs that are susceptible for secondary injury due to stress-induced adrenergic surge. However, the use of BB in traumatic brain injury (TBI) patients is not yet the standard of care which necessitates clear scientific evidence to be used. The BBTBBT study aims to determine whether early administration of propranolol based on the high-sensitive troponin T(HsTnT) status will improve the outcome of TBI patients. We hypothesized that early propranolol use is effective in reducing 10- and 30-day mortality in TBI patients. Secondary outcomes will include correlation between serum biomarkers (troponin, epinephrine, cytokines, enolase, S100 calcium binding protein B) and the severity of injury and the impact of BB use on the duration of hospital stay and functional status at a 3-month period. METHODS: The BBTBBT study is a prospective, randomized, double-blinded, placebo-controlled three-arm trial of BB use in mild-to-severe TBI patients based on the HsTnT status. All enrolled patients will be tested for HsTnT at the first 4 and 6 h post-injury. Patients with positive HsTnT will receive BB if there is no contraindication (group 1). Patients with negative HsTnT will be randomized to receive either propranolol (group 2) or placebo (group 3). The time widow for receiving the study treatment is the first 24 h post-injury. DISCUSSION: Early BB use may reduce the catecholamine storm and subsequently the cascade of immune and inflammatory changes associated with TBI. HsTnT could be a useful fast diagnostic and prognostic tool in TBI patients. This study will be of great clinical interest to improve survival and functional outcomes of TBI patients. TRIAL REGISTRATION: ClinicalTrials.gov NCT04508244. Registered on 7 August 2020. Recruitment started on 29 December 2020 and is ongoing.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. El-Menyar A, Asim M, Bahey AA, et al. Beta blocker use in traumatic brain injury based on the high-sensitive troponin status (BBTBBT): methodology and protocol implementation of a double-blind randomized controlled clinical trial. Trials. 2021. PMID: 34876207. doi:10.1186/s13063-021-05872-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。